Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. - Wikidata - awgldk - TriplyDB

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

http://www.wikidata.org/entity/Q33349461

about

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement Venous thromboembolic disease Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3 A comparison of lepirudin and argatroban outcomes Atomic description of the immune complex involved in heparin-induced thrombocytopenia Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.New developments in diagnosis and treatment of heparin-induced thrombocytopenia.Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor.Diagnosis and management of heparin-induced thrombocytopenia.Coronary artery stent thrombosis associated with heparin-induced thrombocytopenia: case report and review of the literature.Direct thrombin inhibitors: pharmacology and clinical relevance.Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia from venous thromboembolism treatment.Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives.Treatment of heparin-induced thrombocytopenia in cardiovascular patients.Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital.Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.Bilateral lower extremity gangrene requiring amputation associated with heparin-induced thrombocytopenia--a case report.Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: case report and review of the literature.Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis.Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia: treatment options and special considerations.Testing for heparin-induced thrombocytopenia: are we there yet?Bilateral lower extremity gangrene requiring amputation associated with heparin-induced thrombocytopenia: a case report.Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia.Argatroban therapy in patients with coronary artery disease and heparin-induced thrombocytopenia.Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.Current concepts review: heparin-induced thrombocytopenia.Review: recent advances in argatroban-warfarin transition in patients with heparin-induced thrombocytopenia.Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.Evaluation of a clinical scoring scale to direct early appropriate therapy in heparin-induced thrombocytopenia.Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT.Heparin-induced thrombocytopenia: overview and treatment.Update on the clinical applications of argatroban.

P2860

Q24235993-2D9339EC-BACB-400B-83DA-7250040A414D Q24631121-EB4FF2FB-5507-4848-8C15-6EA6126EE6D9 Q28261518-0BDD824E-1C68-461C-A081-F48A1F4DB7A6 Q28278419-D4B25E51-D010-4A47-8842-4B8E16A7CF04 Q28278668-9B619A2A-9EBE-47B3-9700-EF92426AB11A Q30665349-FB1D21F7-170B-4E45-8150-2EEF23FAE0B8 Q33364404-40DA8BE1-F31F-46CE-803D-FF6914DA8292 Q33364828-E3C10F3D-7657-4BC7-9558-FF1410D064E4 Q33365108-2B0247BC-09C5-40BA-8E4C-A9AADCDF0F14 Q33365985-BE5538C0-0D28-4073-A2B1-9A7CA22F640E Q33366197-FE362D54-B09C-4540-9FC8-916849FE3BE3 Q33366516-5ABE2C8A-B741-4A4F-A2EA-4B47C7A97732 Q33368191-E94AE29E-4FCA-4F2E-8BD3-20968AAF8A95 Q33369316-1CA7590F-56DA-43F9-A069-FF6F92D587C8 Q33369330-9746C087-26A0-4A19-BA86-7C31CA1B8760 Q33369355-2460935D-D843-4F75-9FA3-B482D6CD774B Q33369690-0A8126AD-AC8B-47E6-B497-E7FBB8F49AF7 Q33370137-B631ED9C-BB41-4CA7-8293-CAC96DB33246 Q33370566-24CDA8A0-A5B8-4DDA-B85F-6A8FDE60EE97 Q33370636-79180502-06B7-4E72-84B2-7CA9207521F4 Q33370696-FC518FE5-7D1B-45D4-9E0E-17B0722723BF Q33370778-19FFFEBF-7825-467E-B872-B4F2C75899FB Q33372751-32BB5EE0-E0F1-4442-889C-640696A94CD9 Q33373025-E7F11775-E484-47AA-811E-6778DA0CCAA0 Q33373700-BD57D529-BE93-434A-9FEF-5B405CEB9E02 Q33374658-8E05CABC-A52D-4915-ABF5-C98EE0B2DB5F Q33374916-19623B7F-9EFC-4CE2-A135-652D166AE7B6 Q33375221-7FF6208C-994D-4F4B-83BF-ACA8AC51C9A3 Q33375376-26839531-99C1-40AB-8B9E-D4B32EEB7D7F Q33376409-BE69E4EB-8E3E-48FF-86CD-C6F8D7437535 Q33376889-6C1AFF11-A103-46E0-B887-BA1EE7AC9636 Q33380931-CF33D119-093E-4072-931E-FA9F7897CA89 Q33382108-5C23033E-FD5C-4BDD-91BA-65C54F0366E6 Q33382275-FECC3A6D-BE55-4AB4-BA12-EA612997FAE3 Q33382677-610D857C-EBF6-4B4C-BF9D-38BD6232D44E Q33385898-207E4E5D-5F6A-4324-B310-A3EFF812630D Q33385916-52B68A3E-52F6-48EE-976F-081BF31CBD06 Q33385970-6A884C0E-1114-4EF9-98BB-9AC71987798C Q33386197-023940CE-05F2-48C2-BA16-2B4EB4B3A581 Q33386502-0C655D9F-5286-4C0A-9654-B477C2CC58FD

P2860

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

http://www.wikidata.org/entity/Q33349461

description

2003 nî lūn-bûn

@nan

2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

@ast

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

@en

type

label

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

@ast

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

@en

prefLabel

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

@ast

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

@en

P1433

Q33349461-BA3FB043-EE7F-41BC-BDEF-FFB05C96B69C

P1476

Q33349461-EDC793E6-057F-4003-BE94-8795AD756B89

P2093

Q33349461-2C654A95-9004-48D5-8C8C-C38B0F16948F

Q33349461-2EF2AB6B-6828-413D-8CF1-C8F5FF47DA32

Q33349461-37228635-ECCF-4D3F-BE62-40779465A2E4

Q33349461-C462F98C-F216-4787-9721-79E06252E344

Q33349461-DBEEA175-90B1-4DB5-A13D-02E4A006FDE1

Q33349461-FFAFDFFB-497E-4CA3-BC17-898DBBB9A0B6

P304

Q33349461-B19B0426-3661-4E22-A000-C42FFE8A29B4

P31

Q33349461-4A07BB46-50DD-4DC0-B3B3-48C539BC3D33

P356

Q33349461-FA62B85B-4A22-4353-B729-111CF90CC2A0

P407

Q33349461-77089F86-33A0-4297-9C74-17650176AF47

P433

Q33349461-3608C932-0142-4A18-8EF6-6DF956E31A1A

P478

Q33349461-097365B2-536D-446A-BEBF-AEC01D764D86

P577

Q33349461-7700640A-D046-48C7-9675-93C25054FDD0

P5875

Q33349461-969E7EDA-2FFA-42E3-B1B2-53F98C928862

P698

Q33349461-5CD86E53-48A6-43F2-BAAD-FB286923A251

P921

Q33349461-268FA4A5-BF57-41F8-AF0D-55C7A8F179A6

Q33349461-F0F73E49-8EA4-4354-AD78-2EEB521C4677

P356

ARCHINTE.163.15.1849

P1433

JAMA Internal Medicine

P1476

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

@en

P2093

Argatroban-915 Investigators

http://www.w3.org/2001/XMLSchema#string

Bruce E Lewis

http://www.w3.org/2001/XMLSchema#string

Diane E Wallis

http://www.w3.org/2001/XMLSchema#string

Fred Leya

http://www.w3.org/2001/XMLSchema#string

John G Kelton

http://www.w3.org/2001/XMLSchema#string

Marcie J Hursting

http://www.w3.org/2001/XMLSchema#string

P304

1849-1856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHINTE.163.15.1849

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

163

http://www.w3.org/2001/XMLSchema#string

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10618023

http://www.w3.org/2001/XMLSchema#string

P698

12912723

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia

anticoagulation